Cavo M; Tosi P; Zamagni E; Cellini C; Tacchetti P; Patriarca F; Di Raimondo F; Volpe E; Ronconi S; Cangini D; Narni F; Carubelli A; Masini L; Catalano L; Fiacchini M; de Vivo A; Gozzetti A; Lazzaro A; Tura S; Baccarani M., Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study., «JOURNAL OF CLINICAL ONCOLOGY», 2007, 25, pp. 2434 - 2441 [articolo]
Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S., 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma., «WORLD JOURNAL OF SURGICAL ONCOLOGY», 2007, 5, pp. 68 - 68 [articolo]
C. Nanni; V. Ambrosini; E. Zamagni; M. Farsad; P. Castellucci; M. Sansovini; D. Rubello; G. Montini; M. Cavo; S. Fanti., Comparison between 18F-FDG PET/CT and 11C-Choline PET/CT for the evaluation of multiple myeloma, in: , «THE JOURNAL OF NUCLEAR MEDICINE», 2006, 47S, pp. 478p - 478p (atti di: SNM annual meeting,, 3-7 June,, San Diego, USA.) [atti di convegno-abstract]
Tosi P; Zamagni E; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Baccarani M; Cavo M., Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation., «ANNALS OF HEMATOLOGY», 2006, 85(8), pp. 549 - 551 [articolo]
Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M., First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma., «EUROPEAN JOURNAL OF HAEMATOLOGY», 2006, 76, pp. 399 - 404 [articolo]
Palumbo A; Bringhen S; Caravita T; Merla E; Capparella V; Callea V; Cangialosi C; Grasso M; Rossini F; Galli M; Catalano L; Zamagni E; Petrucci MT; De Stefano V; Ceccarelli M; Ambrosini MT; Avonto I; Falco P; Ciccone G; Liberati AM; Musto P; Boccadoro M; Italian Multiple Myeloma Network; GIMEMA., Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial., «THE LANCET», 2006, 367(9513), pp. 825 - 831 [articolo]
Tosi P; Zamagni E; Cangini D; Tacchetti P; Di Raimondo F; Catalano L; D'ArcoA; Ronconi S; Cellini C; Offidani M; Perrone G; Ceccolini M; Brioli A; Tura S;Baccarani M; Cavo M., Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone., «BLOOD», 2006, 108, pp. 3951 - 3952 [articolo]
Cavo M; Terragna C; Renzulli M; Zamagni E; Tosi P; Testoni N; Nicci C; Cangini D; Tacchetti P; Grafone T; Cellini C; Ceccolini M; Perrone G; Martinelli G; Baccarani M; Guardigni L., Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission., «JOURNAL OF CLINICAL ONCOLOGY», 2006, 24, pp. e4 - e5 [articolo]
Nanni C.; Zamagni E.; Farsad M.; Castellucci P.; Tosi P.; Cangini D.; Salizzoni E.; Canini R.; Cavo M.; Fanti S., Role of (18)F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results., «EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING», 2006, 33(5), pp. 525 - 531 [articolo]
C. Nanni; V. Ambrosini; E. Zamagni; M. Farsad; P. Castellucci; M. Cavo; V. Allegri; C. Pettinato; G. Montini; S. Fanti., Use of 18 FDG PET/CT to evaluate therapy response of bone myelomatous lesions, in: , «THE JOURNAL OF NUCLEAR MEDICINE», 2006, 47S, pp. 52p - 52p (atti di: SNM annual meeting, 3-7 June, San Diego, USA) [atti di convegno-abstract]
TOSI P; ZAMAGNI E; CELLINI C; PLASMATI R; CANGINI D; TACCHETTI P; PERRONE; G; PASTORELLI F; TURA S; BACCARANI M.; CAVO M., Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma., «EUROPEAN JOURNAL OF HAEMATOLOGY», 2005, 74, pp. 212 - 216 [articolo]
CAVO M; ZAMAGNI E; TOSI P; TACCHETTI P; CELLINI C; CANGINI D; DE VIVO A; TESTONI N; NICCI C; TERRAGNA C; GRAFONE T; PERRONE G; CECCOLINI M; TURA S; BACCARANI M.; BOLOGNA STUDY., Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for
autologous transplantation for multiple myeloma., «BLOOD», 2005, 106, pp. 35 - 39 [articolo]
Fanti S.; Yu JQ; Moretti A.; Farsad M.; Nanni C.; Zamagni E.; Cellini C.; Tosi P.; Zhuangh H.M.; Cavo M.; FRanchi R.; Canini R.; Monetti N.; Alavi A., Assessmen of disease ativity in multiple myeloma with FDG-PET imaging, in: , «EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING», 2004, 2, pp. 285 - 285 (atti di: Abstract Annual Congress of the EANM, Helsinki, 31/08/2004) [atti di convegno-abstract]
Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; de Vivo A; Palareti G; Tura S; Baccarani M., First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma., «HAEMATOLOGICA», 2004, 89, pp. 826 - 831 [articolo]
TOSI P; ZAMAGNI E; CELLINI C; CANGINI D; TACCHETTI P; TURA S; BACCARANI M.; CAVO M., Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure., «EUROPEAN JOURNAL OF HAEMATOLOGY», 2004, 73, pp. 98 - 103 [articolo]
